Rallybio to acquire Avenzo Therapeutics in combined merger and $215 million financing deal
Rallybio (NASDAQ:RLYB) and Avenzo Therapeutics announced Monday that they have entered into a definitive agreement to combine through a merger transaction.
Rallybio (NASDAQ:RLYB) and Avenzo Therapeutics announced Monday that they have entered into a definitive agreement to combine through a merger transaction.
Binance has launched commission-free trading for more than 7,000 US stocks and exchange-traded funds, marking its latest step toward becoming a multi-asset financial platform.
Rocky Mountain Chocolate Factory (NASDAQ:RMCF) reported its financial and operating results for the fiscal fourth quarter and full year ended February 28, 2026, revealing a planned contraction in lower-margin sales alongside structural improvements in its underlying expense profile and product profit margins.
European Central Bank Executive Board member Isabel Schnabel warned that stablecoins could bring traditional financial-market risks into tokenised finance while further strengthening the global dominance of the US dollar.
SOLAI (NYSE:SLAI) has reached an agreement to acquire a controlling interest in a Singaporean artificial intelligence developer, accelerating its corporate pivot away from cryptocurrency mining operations toward an AI-first infrastructure platform.
Coinbase has launched direct Indian rupee banking services in India, allowing customers to transfer funds between local bank accounts and the exchange through the Immediate Payment Service network.
ParaZero Technologies (NASDAQ:PRZO) has secured its first commercial order from an unnamed U.S.-based Tier-1 defense corporation for its proprietary DefendAir Net Pods.
Welltower (NYSE:WELL) has announced that it expects to increase its quarterly common dividend by 15% to $0.85 per share, beginning with the second quarter of 2026.
A $1.26 billion block trade in BlackRock’s iShares Bitcoin Trust last week was likely a large investor exiting a concentrated Bitcoin position rather than unwinding a market-neutral strategy, according to NYDIG.
AstraZeneca (NASDAQ:AZN) unveiled positive data from its late-stage EMERALD-3 clinical trial on Monday, demonstrating that adding its dual-immunotherapy regimen to standard localized therapy significantly slows disease progression in patients battling early-stage, unresectable liver cancer.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy